Hoitt Jason 4

What Happened
Jason Hoitt, Chief Patient Officer at Stoke Therapeutics (STOK), disposed of a total of 3,712 shares via open‑market sales on March 17–18, 2026, for aggregate proceeds of approximately $119,312. Individual reported transactions: 1,033 shares @ $32.74 ($33,820), 748 shares @ $33.38 ($24,965), 1,762 shares @ $31.28 ($55,122), 139 shares @ $31.79 ($4,419), and 30 shares @ $32.85 ($986). These sales are reported under sale code "S."

Key Details

• Dates: March 17, 2026 (two sales) and March 18, 2026 (three sales); Form 4 filed March 19, 2026 (timely).
• Transaction type: Sales (code S); footnote F1 indicates these were issuer‑mandated sales to satisfy tax withholding related to restricted stock unit (RSU) vesting/settlement.
• Price reporting: Reported prices are weighted averages; per footnotes the individual trades occurred across price ranges: $31.995–$32.99, $33.00–$33.855, $30.59–$31.58, and $31.60–$32.46. The filer can provide exact breakdowns on request.
• Shares owned after transaction: Not specified in the supplied excerpt of the filing—see the full Form 4 for post‑transaction holdings.
• Filing timeliness: Filed March 19, 2026 — appears timely relative to the transaction dates.

Context
These sales were routine, issuer‑mandated dispositions to cover tax withholding on RSU vesting (per F1), which is a common administrative action and not itself a directional signal about insider sentiment. The weighted‑average pricing and price ranges reflect multiple smaller trades executed on the listed dates. For complete holdings and exact per‑trade breakdowns, consult the full Form 4 filing (Accession No. 0001762572-26-000006).